Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Ewing 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Colorectal Neoplasms 1

Interventions

Filgrastim 9Ifosfamide 8Etoposide 8Doxorubicin 8Cyclophosphamide 8Vincristine 7X-Rays 6Radiotherapy 6Phantoms, Imaging 6Magnetic Resonance Spectroscopy 6Specimen Handling 5Nuclear Medicine Department, Hospital 5Topotecan 4Peripheral Blood Stem Cell Transplantation 4Melphalan 4Irinotecan 4Biopsy 4Thiotepa 3Imatinib Mesylate 3Carboplatin 3Bevacizumab 3ulixertinib 2tipifarnib 2temsirolimus 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neuroectodermal Tumors, Primitive, Peripheral × robatumumab × Clear all
NCT00617890 2018-08-23

A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)

Merck Sharp & Dohme LLC

Phase 2 Terminated
219 enrolled 13 charts
Sarcoma

Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡